Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Bromodomain and extraterminal (BET) proteins: biological functions, diseases and targeted therapy
Zhiqiang Wang, Zhao-Cong Zhang, Yuyang Wu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 46

Showing 1-25 of 46 citing articles:

Molecular hybridization: a powerful tool for multitarget drug discovery
Pedro de Sena Murteira Pinheiro, Lucas Silva Franco, Tadeu L. Montagnoli, et al.
Expert Opinion on Drug Discovery (2024) Vol. 19, Iss. 4, pp. 451-470
Closed Access | Times Cited: 28
Epigenetic modulations in triple-negative breast cancer: Therapeutic implications for tumor microenvironment
Linlin Zhou, Danny Yu
Pharmacological Research (2024) Vol. 204, pp. 107205-107205
Open Access | Times Cited: 9
Epigenetics-targeted drugs: current paradigms and future challenges
Wanlin Dai, Xinbo Qiao, Yuanyuan Fang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 6
Targeting protein synthesis pathways in MYC-amplified medulloblastoma
Devendra Kumar, Ranjana Kanchan, Nagendra K. Chaturvedi
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access
Prostate cancer epigenetics — from pathophysiology to clinical application
Vera Constâncio, João Lobo, José Pedro Sequeira, et al.
Nature Reviews Urology (2025)
Closed Access
LMNA-related cardiomyopathy: From molecular pathology to cardiac gene therapy
Ze Wang, Jiahao Wu, Zhongwei Lv, et al.
Journal of Advanced Research (2025)
Open Access
Leveraging Epigenetic Alterations in Pancreatic Ductal Adenocarcinoma for Clinical Applications
Jörg Tost, Secil Ak-Aksoy, Daniele Campa, et al.
Seminars in Cancer Biology (2025)
Open Access
SMARCA2 protein: structure, function and perspectives of drug design
Zhaolin Guo, Peng Wang, Yuxuan Han, et al.
European Journal of Medicinal Chemistry (2025), pp. 117319-117319
Closed Access
PROTAC technology for prostate cancer treatment
Zhen Wang, Dingpeng Zhang, Hiroyuki Inuzuka, et al.
Acta Materia Medica (2025) Vol. 4, Iss. 1
Open Access
Consensus, debate, and prospective on pancreatic cancer treatments
Junke Wang, Jie Yang, Amol Narang, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 4
Non-oncogene dependencies: Novel opportunities for cancer therapy
Tiziana Di Marco, Mara Mazzoni, Angela Greco, et al.
Biochemical Pharmacology (2024) Vol. 228, pp. 116254-116254
Closed Access | Times Cited: 3
Targeted Protein Degradation (TPD) for Immunotherapy: Understanding Proteolysis Targeting Chimera-Driven Ubiquitin-Proteasome Interactions
Rajamanikkam Kamaraj, Subhrojyoti Ghosh, Souvadra Das, et al.
Bioconjugate Chemistry (2024) Vol. 35, Iss. 8, pp. 1089-1115
Open Access | Times Cited: 3
Novel potent molecular glue degraders against broad range of hematological cancer cell lines via multiple neosubstrates degradation
Pengyun Li, Xiaotong Hu, Zhiya Fan, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 3
NSD3 in Cancer: Unraveling Methyltransferase-Dependent and Isoform-Specific Functions
Yanara Nuñez, Sebastian Vera, Victor Baeza, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 944-944
Open Access | Times Cited: 2
NUT-midline carcinoma of the lung with rare BRD3-NUTM1 fusion
Prerana Jha, Vaishakhi Trivedi, Nandini Menon, et al.
Cancer Research Statistics and Treatment (2024) Vol. 7, Iss. 1, pp. 110-116
Open Access | Times Cited: 2
Co-inhibition of BET and NAE enhances BIM-dependent apoptosis with augmented cancer therapeutic efficacy
Qian Zhang, Qian Wu, Xia‐Juan Huan, et al.
Biochemical Pharmacology (2024) Vol. 223, pp. 116198-116198
Closed Access | Times Cited: 2
BET inhibitors (BETi) influence oxidative phosphorylation metabolism by affecting mitochondrial dynamics leading to alterations in apoptotic pathways in triple‐negative breast cancer (TNBC) cells
Teresa Rossi, Egidio Iorio, Mattea Chirico, et al.
Cell Proliferation (2024) Vol. 57, Iss. 12
Open Access | Times Cited: 2
Breaking the Barrier: Epigenetic Strategies to Combat Platinum Resistance in Colorectal Cancer
Shiwen Luo, Yue Ming, Dequan Wang, et al.
Drug Resistance Updates (2024) Vol. 77, pp. 101152-101152
Open Access | Times Cited: 2
Targeting of TAMs: can we be more clever than cancer cells?
Julia Kzhyshkowska, Jiaxin Shen, Irina Larionova
Cellular and Molecular Immunology (2024) Vol. 21, Iss. 12, pp. 1376-1409
Open Access | Times Cited: 2
Strategies to enhance the response of liver cancer to pharmacological treatments
José J.G. Marı́n, Rocı́o I.R. Macı́as, Maitane Asensio, et al.
AJP Cell Physiology (2024) Vol. 327, Iss. 1, pp. C11-C33
Closed Access | Times Cited: 1
PROteolysis‐Targeting Chimeras (PROTACs) in leukemia: overview and future perspectives
André T. S. Vicente, Jorge A. R. Salvador
MedComm (2024) Vol. 5, Iss. 6
Open Access | Times Cited: 1
mRNA Display in Cell Lysates Enables Identification of Cyclic Peptides Targeting the BRD3 Extraterminal Domain
Catherine A. Hurd, Jacob T. Bush, Andrew J. Powell, et al.
Angewandte Chemie International Edition (2024) Vol. 63, Iss. 38
Open Access | Times Cited: 1
AI in Pharma: Transforming Drug Discovery and Strategic Management with MYC-Modulating Compounds and BET Protein Inhibitors
Robert B. Kargbo
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 3, pp. 334-336
Open Access | Times Cited: 1
Targeting bromodomian-containing protein 8 (BRD8): An advanced tool to interrogate BRD8
Tingting Wu, Yali Chen, Qidong You, et al.
European Journal of Medicinal Chemistry (2024) Vol. 268, pp. 116271-116271
Closed Access | Times Cited: 1
Development and Evaluation of [11C]I-58: A Novel PET Radiotracer Targeting BRD4 BD2 for Advanced Epigenetic Imaging
Yanli Wang, Yongle Wang, Yulong Xu, et al.
ACS Omega (2024)
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top